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Bone metastasisMetastatic cells switch between different modes of migration through supramolecular plasticity mechanism(s)
still largely unknown. The aimof thepresent paperwas to clarify somemolecular aspects of the epigenetic control
ofmigration of 1833-bonemetastatic cells compared toMDA-MB231-parentalmammary carcinoma cells. Active
c-Src overexpression enhanced 1833-cell spontaneous migration and CXCR4-mediated chemoinvasion toward
CXCL12 ligand. Only inmetastatic cells, in fact, c-Src seemed to stabilize nuclear CXCR4-protein receptor possibly
due to tyrosine phosphorylation, by impairingprotein-degradative smear and causing instead anelectrophoretic-
mobility shift; the cytosolic steady-state level of CXCR4 was enhanced, and the protein appeared also
phosphorylated. These ﬁndings suggested the triggering of unique signaling pathways in metastasis for homing
of breast-cancer cells to congenial environment of speciﬁc organs. Microenvironmental stimuli activating c-Src
might inﬂuence Ets1 binding to CXCR4 promoter and consequent transactivation, as well as CXCR4 post-
translational regulatory mechanisms such as phosphorylation. Enhancement of Ets1 activity and CXCR4
induction by c-Src overexpression were prevented by histone deacetylase (HDAC) blockade. In contrast, HDAC
inhibition with trichostatin A increased cytosolic phosphorylated CXCR4 expression in MDA-MB231 cells, but
Ets1 involvement was practically unneeded. c-Src might be suggested as a bio-marker predicting metastasis
sensitivity patterns to HDAC inhibitors. Rationally designed and individualized therapy may become possible as
more is learned about the target molecules of HDAC's inhibitory agents and their roles, as undertaken for CXCR4
that is likely to be crucial for homing, angiogenesis and survival in a c-Src-dependentmanner in bone-metastatic
mammary cells.ilano, Dipartimento Morfologia
athology Laboratory, via Luigi
34; fax: +39 0250315338.
).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The tyrosine kinase c-Src is involved in the regulation of a range of
cellular processes, including proliferation/survival, adhesion, motility
and bone metabolism. There is evidence for a role of c-Src in
tumorigenesis and in osteoclastic activity associated with bone
metastasis [1]. c-Src activity is higher in metastasis from colon cancer
than in both primary tumor tissue and in cells with limited metastatic
potential [2–4]. Greater metastatic potential and worse prognosis for
colorectal cancer are, therefore, associated with active c-Src [5].
For bone metastasis of breast cancer few data are available. In a
mouse model of breast cancer, c-Src inhibition reduces the incidence
of bone metastases, increasing the survival [6]. c-Src-responsive
signature (SRS), consisting of a group of genes that are expressed
when c-Src is active, characterizes breast carcinomas that relapse tobone. SRS seems more effective than estrogen-responsive status in
identifying breast cancer patients who would develop bone metas-
tases [7].
Recently, we have shown some key molecular mechanisms
implicated in the c-Src role in breast carcinoma invasiveness, considered
a prerequisite for metastatic capacity. c-Src mediates transduction
signals downstream of Met-tyrosine kinase, the speciﬁc receptor of
hepatocyte growth factor (HGF) [8,9]. HGF/Met couple is critical for the
cross-talk between breast cancer metastasis and the bone microenvi-
ronment [9,10]. Only in human 1833 clone—with bone metastatic
capacity—HGF stabilizes plasma membrane and nuclear Met, that co-
precipitates with phospho-c-Src (pSrc). Differently, in parental-breast
cancer MDA-MB231 cells Met is rapidly down-regulated after HGF
exposure as well as after histone deacetylase (HDAC) inhibition with
trichostatin A (TSA) [9,11]. In invasive MDA-MB231 cells, HGF also
causes HDAC3 phosphorylation via c-Src, possibly reducing NF-κB
activity and decreasing CXCR4 protein level [8].
In breast cancer, CXCR4 is the most abundantly expressed
chemokine receptor [12], and is observed in 33–55% of primary
mammary carcinomas [13,14]. CXCR4 expression is associated with
shorter disease-free survival and increased risk of recurrence. CXCR4
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parameters of tumor aggressiveness, with potential value as diagnos-
tic and prognostic marker. Site-speciﬁc phosphorylation of CXCR4 is
dynamically regulated by multiple kinases resulting in both positive
or negative modulation of CXCR4 signaling [15]. Nuclear CXCR4
localization seems important for breast tumor progression [13,16,17],
and we have shown CXCR4 in nuclei of 1833-bone metastatic cells
[10]. CXCR4 protein is detected in 67% of bone metastasis samples,
being 3-times more than in visceral metastases [14]. However, CXCR4
expression is lower in lymph node metastasis than in primary breast
cancers [18].
CXCL12 ligand binding to CXCR4 promotesmigration, invasion and
adhesion of breast cancer cells in vitro[13,19]. Noteworthy, HGF
differently inﬂuences spontaneous and CXCL12-stimulated cell
migration depending on the aggressiveness of breast cancer cells, as
reported by us for MCF-7 (low invasive) versus MDA-MB231 (highly
invasive) cells [11]. Because of CXCR4 regulation by cyclooxygenase-2
signaling, that mediates the hypoxic response, a crucial role of this
molecular network in the homing and angiogenesis of 1833-bone
metastasis has been suggested [10]. Also, CXCR4 overexpression
seems to enhance the metastatic phenotype of breast cancer cells in
vivo [20–22]. These effects might be partly due to CXCL12-triggered
transactivation of CXCR4, mediated by EGF and HER2 receptors in a
c-Src-dependent manner [23].
The aim of the present paper was to extend and deepen the
knowledge about the role of c-Src, as key molecular regulator of
human-bone metastasis of breast cancer, by controlling CXCR4
expression through Ets1 activity. To this scope, we comparatively
examined 1833-bone metastatic clone and the parental-invasive
MDA-MB231 cells. In this context, the role of acetylation on c-Src/Ets1
signaling was considered by HDAC blockade with TSA or speciﬁc
knocking-down. Acetylation results from the balance between the
opposite activities of histone acetyltransferases and HDACs. Many
non-histone proteins have been identiﬁed to be the substrates of
HDACs, such as proteins involved in transcription (p53, NF-κB, etc.),
hormone response, nuclear transport, DNA repair, Wnt signaling
(β-catenin) and heat-shock/chaperone response (HSP90) [24,25].
HDACs seem to regulate also c-Src activity, and TSA inhibits c-Src
promoters [11,26]. Generally, increased levels of histone acetylation
(hyperacetylation) are associated with enhanced transcriptional activ-
ity, whereas decreased levels of acetylation (hypoacetylation) are
associated with repression of gene expression [27,28], even if opposite
regulation can also occur. No data are available on Ets1-activity control
via acetylation in the bone metastatic process of breast cancer. The
correlation with uPA levels and metalloproteinase expression leads to
suppose that Ets1mayplaya role inhumanbreast cancermetastasis and
metastatic cell invasiveness [29,30].
The reasoning of our work was to evaluate in 1833 versus MDA-
MB231 cells the correlation and the reciprocal inﬂuence of molecular
events, possibly involved in invadopodia formation and functioning.
Carcinoma cells utilize invadopodia to degrade extracellular matrix
during invasion and metastasis [31], and endogenous c-Src has been
shown to promote invadopodia formation in response to growth
factors and chemokines. Abl-kinase and the chemokine receptor
CXCR4 are downstream of CXCL12, serum growth factors and
activated c-Src [32]. Epigenetic control mechanisms are likely to
inﬂuence tumor aggressive phenotype [33]. Few data are available,
however, about the differences in spontaneous and CXCL12/CXCR4-
mediated speciﬁc chemoinvasion, in the molecular events involved
and in the regulatory acetylation mechanisms occurring between
poorly and highly bone-metastatic cells.
Preliminary ﬁndings in MDA-MB231 cells indicate a role of Ets1 in
CXCR4 expression due to HGF, a microenvironmental signal that might
inﬂuence acetylation [11], but is unknown the role played by Ets1
downstreamof c-Src in the epigenetic control of phenotype plasticity of
metastatic cells, possibly important for the bone avidity via CXCR4.2. Materials and methods
2.1. Reagents
TSA was from Sigma Chemical Co. (St. Louis, MO). Recombinant-
human CXCL12 and anti-CXCR4monoclonal antibody (MAB-182) were
from R&D Systems (Abingdon, UK). Anti-Ets1 (C20), anti-vinculin and
anti-B23 antibodies were purchased from Santa-Cruz Biotechnology
(Santa-Cruz, CA). Anti-c-Src (clone GD11), anti-phospho-c-Src(Tyr
416), anti-phosphotyrosine (anti-pTyr) (clone 4G10) and anti-HDAC1
were from Upstate Biotechnology (Lake Placid, NY). Anti-HDAC3
antibody was from Cell Signalling (Beverly, MA). Fugene 6 was from
Roche Applied Science (Germany). Lipofectamine 2000 was from
Invitrogen (Milan, Italy). pRL-TK (Renilla luciferase) was from Promega
(Madison, WI). siRNA sequences, 5′-CGUACGCGGAAUACUUCGATT-3′
(siRNA LUC, control); 5′-CAGCGACUGUUUGAGAACCTT-3′ (HDAC1.1)
and 5′-CUAAUGAGCUUCCAUACAATT-3′ (HDAC1.3) for siRNA HDAC1;
5′-GAUGCUGAACCAUGCACCUTT-3′ for siRNAHDAC3,were synthesized
byMWG (Ebersberg, Germany). All other chemicals were of the highest
grade available.
2.2. Cell cultures
The human breast carcinoma cells MDA-MB231 and the bone
metastatic 1833 clone, derived from MDA-MB231 cells, were a kind
gift of J. Massagué (Memorial Sloan-Kettering Cancer Center, New
York). The cells were maintained in DMEM containing 10% fetal
bovine serum (FBS). TSA (2.5 μM) treatment was performed for 24 h
in 10% FBS containing medium [11].
2.3. Plasmids
c-Src wild-type (Srcwt) expression vector was from S. Parson
(University of Virginia, Charlottesville, VA); the dominant negative for
Ets1 (ΔEBHHB, ΔEts1) was from J. Ghysdael (Institut Curie, Orsay,
France). The CXCR4(−600/+19)Luc construct was obtained from the
original gene reporter CXCR4(−2632/+86)Luc, kindly provided as
pGL2 basic-construct by A.J. Caruz (Universidad de Jaen, Madrid,
Spain), as previously described [34]; the mutated CXCR4(−600/+19)
Luc was prepared by deleting two bases inside the p65-consensus site
core, as previously described [11]. The gene reporter plasmid NFkBLuc
containing three NF-κB consensus sequences was from M. Hung
(Anderson Cancer Center, Huston, TX); pGL3PGK6TKp containing six
HRE was from P.J. Ratcliffe (Welcome Trust Center for Human Genetics,
Oxford, UK).
2.4. Matrigel invasion assay
Invasion assays were carried out usingMatrigel invasion chambers
from BD Biocoat Cellware (Becton Dickinson Labware, Bedford, MA)
[34]. Cultured cells, transiently transfected or not with 2.5 μg of Srcwt
per 106 cells, or treated for 24 hwith TSA (2.5 μM)were harvested, re-
suspended in medium without serum, added (8×104 per well) in
triplicate to the upper chambers, and allowed to invade through
Matrigel in the absence of serum in the medium. In some
experiments, CXCL12 (200 ng/ml) was added to the bottom chamber
to evaluate chemoinvasion through Matrigel. The cells that had
invaded the lower surface of the membrane were ﬁxed, stained and
counted.
2.5. Transient transfection assay
The cells, seeded in 24-multiwell plates, were transfected with a
DNA/Fugene 6 mixture containing 200 ng of each of the following
constructs: wild type or mutated CXCR4Luc, NFkBLuc, HRELuc or
Srcwt-expression vector. In some experiments, 1 μg per well of ΔEts1
Fig. 1. Invasiveness in Srcwt- and TSA-treated cells. (A) Control and treated cells were
used for Matrigel invasion assay, adding culture medium without serum to the
chambers. To estimate spontaneous invasion, we counted (magniﬁcation ×200) the
invading cells on the lower side of the membrane after staining. Representative images
are shown, and the numbers at the bottom are the mean±S.E. of the counts of ten
selected ﬁelds from three independent experiments. *Pb0.05 vs 1833-control cells.
(B) For speciﬁc chemoinvasion of TSA-treated MDA-MB231 cells or Srcwt-transfected
1833 cells, CXCL12 was added to the bottom chamber in the absence of serum. The
histograms report the mean±S.E. of the number of migrated cells in ten selected ﬁelds.
The experiments have been done in triplicate. *Pb0.05; **Pb0.005 vs respective control
cells. °Pb0.05 vs CXCL12-treated MDA-MB231 cells; ΔPb0.05 vs CXCL12-treated 1833
cells.
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pRL-TK (Renilla luciferase) vector, and Fireﬂy/Renilla luciferase
activity ratios were calculated by the software [34].
2.6. Transfection of siRNAs
Some cells seeded in 6-multiwell plates, were transfectedwith 150
nM siRNAs (control, HDAC1 and HDAC3) using Lipofectamine 2000.
Two cycles of siRNA transfection were performed at 24 h interval;
some cells were co-transfected with Srcwt expression vector after the
ﬁrst cycle. The cells, harvested at 72 h, were lysed in urea buffer (8 M
urea, 0.1 M NaH2PO4, 0.01 M Tris, pH 8, and proteinase inhibitors) to
obtain proteins for Western blot analysis, or processed to obtain
nuclear extracts for Electrophoretic mobility shift assay (EMSA) [35].
2.7. EMSA analysis
EMSA was performed as previously described [35]. The oligonu-
cleotide sequence used for EMSA is shown in Fig. 3A. The Octamer-1
binding site sequence, used for loading control, was: 5′-TGCGAATG-
CAAATCACTAGAA-3′. For supergelshift assay, nuclear extracts were
pre-incubated with 1 μg of anti-Ets1 antibody for 15 min at room
temperature, followed by incubationwith the labeled oligonucleotide.
2.8. Immunoprecipitation and Western blot assays
The protein extracts were prepared in the presence of phosphatase
inhibitors to prevent the loss of protein-phosphorylation state.
Protein immunoprecipitation (1 mg of protein) was performed
with 6.5 μg of anti-CXCR4 antibody using 80 μl of protein A Sepharose
(1:1, v:v). Total proteins (100 μg) or nuclear proteins (50 μg) were
analyzed by Western blots. Immunoblots were performed with anti-
CXCR4 (5 μg/ml), anti-pTyr (3 μg/ml), anti-Ets1 (1:1000), anti-cSrc
(1 μg/ml) or anti-phospho-Src (2 μg/ml) antibody [35]. To conﬁrm
equal loading, themembraneswere sequentially immunoblottedwith
anti-vinculin (total extracts) or anti-B23 (nuclear extracts) antibody.
After incubation with the appropriate secondary antibody, the signals
were detected using enhanced chemiluminescence kit (ECL or ECL-
plus; Amersham Biosciences).
2.9. Statistical analysis
The number of migrated cells, densitometric values, and luciferase
activity were analyzed by analysis of variance, with Pb0.05 consid-
ered signiﬁcant. Differences from controls were evaluated on original
experimental data.
3. Results
3.1. Different regulation of invasiveness in MDA-MB231 and 1833 cells
Upon mammary tumor progression, multiple classes of extracel-
lular matrix-degrading enzymes are upregulated and activated,
responsible for spontaneous mesenchymal movement [36–38].
Experiments dealing with the molecular events that might be
implicated in the spontaneous migration were carried out with
MDA-MB231 and 1833 cells, to clarify the possible role of c-Src and
protein acetylation, and to consider the relationship with aggressive-
ness (Fig. 1). To this purpose, we evaluated the effect of the
overexpression of exogeneous c-Src or of the blockade of class I and
II HDACs, to cause acetylation modiﬁcations [39]. Experiments were
performed with Matrigel invasion chamber, that is considered an in
vitro model system for metastasis [40]. In Fig. 1A, representative
images are reported showing that Srcwt transfection and TSA
treatment oppositely affected 1833 spontaneous migration, while
being ineffective in MDA-MB231 cells.Then, we studied speciﬁc chemoinvasion toward CXCL12, added to
the lower chamber of the Matrigel assay system, as shown in Fig. 1B.
In MDA-MB231 cells, CXCL12 in the absence and in the presence of
TSA increased 2.5- and 1.5-fold chemoinvasion, respectively. Srcwt
transfection was ineffective in respect to control (data not shown).
Differently, in 1833 cells speciﬁc chemoinvasion was enhanced 3-fold
by Srcwt transfection. Thus, diverse effects of TSA and Srcwt on
spontaneous and speciﬁc migration were observed in highly invasive
and bone-metastatic cells.
3.2. Evaluation of molecular control mechanisms of CXCR4 expression by
TSA, and role of Ets1
To deepen the knowledge on CXCL12-induced cell invasion, some
CXCR4-transcriptional and post-translational regulatory mechanisms
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CXCR4 promoter region spanning from−600 to+19, with 6 Ets1 and
1 NF-κB (p65) binding sites, and the p65-mutated construct were
used (Fig. 2A) [11,34]. In a ﬁrst series of experiments performed under
TSA exposure (Fig. 2B–D), CXCR4 transactivation and the role played
by Ets1, as well as the protein expression were comparatively
evaluated in MDA-MB231 and 1833 cells.
As shown in Fig. 2B, the mutation of p65 did not modify basal
CXCR4 transactivating activity in MDA-MB231 cells. TSA similarly
stimulated the luciferase activity of both the constructs; ΔEts1
transfection prevented these TSA-stimulatory effects, also reducing
basal luciferase activity. In 1833 cells, Ets1 blockade was inhibitory
only on themutated-construct basal activity, being higher than that of
the wild type. Using total cell extracts (Fig. 2C), in MDA-MB231 cells
TSA enhanced (2.5-fold) CXCR4 protein level (50 kDa band), also
shifting CXCR4-protein migration possibly due to phosphorylation.
Differently, in 1833 cells TSA was ineffective and faint slow migrating
bands were observed under basal and treatment conditions. The Ets1
protein level of control MDA-MB231 cells, that was higher than that of
1833 cells, appeared also phosphorylated, decreasing (−50%) after
TSA treatment.Fig. 2. Transcriptional and post-transcriptional control of CXCR4 by TSA. (A) Constructs co
transiently transfected with the above reported constructs, were treated with TSA or co-
luciferase activity ratios. Columns, mean of three independent experiments done in triplica
TSA-treated cells. (C) Total extracts were used for Western blot analysis. Vinculin was used
MDA-MB231 control value, considered as 1. The experiments were repeated three times w
indicated the ratio pTyr/CXCR4, obtained by using densitometric values after respective imm
MB231 control value, considered as 1. The experiments were repeated three times with simTo better evaluate protein phosphorylation, immunoprecipitates
were performed with anti-CXCR4 antibody blotting with anti-pTyr
antibody (Fig. 2D). Noteworthy, under our experimental conditions
TSA doubled pTyr/CXCR4 ratio in MDA-MB231 cells. We cannot
exclude that also other types of phosphorylation occurred in TSA-
treatedMDA-MB231 cells. In the immunoprecipitates carried out with
1833-protein extracts, CXCR4 protein level seemed 6-fold higher than
in MDA-MB231 cells.3.3. Evaluation of molecular control mechanisms of CXCR4 expression by
Srcwt, and role of Ets1
In a second series of experiments, the role of Ets1 in c-Src
overexpressing cells on CXCR4 luciferase activity and protein
expression were evaluated (Fig. 3). As shown in Fig. 3A, by co-
transfecting 1833 cells with CXCR4Luc wild-type and Srcwt the
luciferase activity was strongly enhanced (about 6-fold), and ΔEts1
was inhibitory. However, in MDA-MB231 cells co-transfection of
ΔEts1 inhibited basal luciferase activity of the wild type- and the
mutated-promoter constructs.ntaining wild type and p65-mutated (mut) CXCR4 promoter fragments. (B) The cells,
transfected with ΔEts1. The histograms report the absolute values for Fireﬂy/Renilla
te; bars, S.E. *Pb0.05, **Pb0.005 vs corresponding control value. °Pb0.05, °°Pb0.005 vs
for normalization. The numbers at the bottom indicate the fold-variations relative to
ith similar results. (D) Total extracts were used for immunoprecipitation. Relative pTyr
unoblotting. The numbers at the bottom indicate the fold-variations relative to MDA-
ilar results.
Fig. 3. Transcriptional and post-transcriptional control of CXCR4 by Srcwt. (A) The cells, transiently transfected with the CXCR4wild type andmutated promoter constructs, were co-
transfected with Srcwt in the presence or not of ΔEts1. The histograms report the relative fold-variations for Fireﬂy/Renilla luciferase activity ratios. Columns, mean of three
independent experiments done in triplicate; bars, S.E. *Pb0.05, **Pb0.005 vs corresponding control value. °°Pb0.005 vs Srcwt-transfected cells. (B) Total extracts were used for
Western blot analysis. Vinculin was used for normalization. The numbers at the bottom indicate the fold-variations relative to MDA-MB231 control value, considered as 1. The
experiments were repeated three times with similar results. (C) Nuclear protein extracts were used for Western blot analysis. B23 was used for normalization. The asterisk indicates
the supposed degradation bands. The experiments were repeated three times with similar results.
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protein level of CXCR4 (50 kDa band), and phosphorylation bands
appeared upstream. In MDA-MB231 cells, however, a remarkable
electrophoretic mobility shift of CXCR4 was shown after Srcwt
transfection, leading to suppose ubiquitination of CXCR4 in agreement
with Malik and Marchese [41]. Ets1 protein level tripled after Srcwt
transfection in the two cell lines, appearing phosphorylated in 1833-
treated cells (Fig. 3B).
Further experiments were performed to evaluate post-translational
protein changes of CXCR4 by Srcwt. Using nuclear extracts (Fig. 3C), we
observed a retardation of electrophoretic mobility of CXCR4 protein in
control 1833 cells, compared to MDA-MB231 cells. After Srcwt
transfection, also a CXCR4-tyrosine phosphorylation band was likely
to appear in 1833-cell nuclei. In contrast, principally in the nuclei of
MDA-MB231 cells, transfected with Srcwt, molecular weight forms of
less than 50 kDa were shown, in agreement with receptor degradation
[42].
Based on these results, in 1833 clone Srcwt seemed to phosphor-
ylate CXCR4while preventing receptor degradation, at differencewith
MDA-MB231 cells. Moreover, Ets1 was important for c-Src-stimulated
CXCR4 transactivation in 1833 cells, even if Ets1 protein level was
similarly affected by Srcwt in both cell lines. Then, speciﬁc
experiments were done, and reported in the following sections
(Sections 3.4 and 3.5) to clarify this point.3.4. Ets1 binding to a consensus sequence of CXCR4 promoter and
regulation by HDACs
We determined Ets1 binding activity to an oligonucleotide
synthesized using the consensus sequence of the CXCR4 promoter,
shown in Fig. 4A. In the CXCR4 promoter, 5 hypoxia inducible factor
responsive elements (HRE) are present, upstream the Ets1 consensus
sequences, consistent with a possible interacting regulatory function
of hypoxia inducible factor-1 (HIF-1) and Ets1 [43].
As shown in Fig. 4B, Ets1–DNA binding was markedly elevated in
MDA-MB231 cells under basal conditions. Differently, in 1833 cells a
huge increase of Ets1–DNA binding was observed after Srcwt
transfection. The speciﬁcity of the Ets1–DNA complex was examined
by competition experiments using 50-fold molar excess of unlabelled
oligonucleotide (50×), which almost completely suppressed the
complex formation. Moreover, supergelshift analyses were done with
control MDA-MB231 and Srcwt-transfected 1833 cells. The preincuba-
tionwith the anti-Ets1 antibody (Ab) disrupted the DNA–Ets1 complex,
causing also a shift (ss) beyond giving immunodepletion. We
investigated the involvement of class I-HDACs 1 and 3 in Ets1–DNA
binding under basal conditions and Srcwt transfection in the two cell
lines. By knocking-down the HDACs with the speciﬁc siRNAs, Ets1-
binding activity in MDA-MB231 cells was partly reduced, while the
Srcwt-stimulated Ets1 binding was abolished in 1833 cells. Octamer-1
Fig. 4. HDACs involvement in Ets1–DNA binding after Srcwt transfection. (A) The oligonucleotide consensus sequence for Ets1, present in CXCR4 promoter, was used for EMSA.
(B) EMSA analyses of Ets1 and Octamer-1 (Oct-1), using nuclear extracts from control and transfected cells. 50×, speciﬁc competition. Supergelshift was performed with anti-Ets1
antibody (Ab), and nuclear extracts from control MDA-MB231 and Srcwt-transfected 1833 cells. The experiments were repeated three times with similar results. (C) Western blots
of total cell extracts after transfection of siRNAs for HDACs, and antiluciferase siRNA as control (siRNACTRL). Vinculin was used for normalization. The blots shown are representative
of three independent experiments. (D) Total cell extracts from Srcwt and siRNA-HDACs co-transfected cells were used forWestern blot analysis. Vinculin was used for normalization.
The numbers at the bottom indicate the fold-variations relative to MDA-MB231 control value, considered as 1. The experiments were repeated three times with similar results.
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HDACs knocking down caused the almost complete disappearance of
HDAC proteins (Fig. 4C). To check the reproducibility of the knocking
down, we used two oligonucleotides for HDAC1, i.e. 1.1 and 1.3.
Srcwt transfection enhanced the levels of c-Src (about 5-fold) and
of pSrc (about 7-fold) in both the cell lines used (Fig. 4D). pSrc is the
active form of the tyrosine kinase [44]. The siRNAs for HDACs were
effective in reducing the c-Src protein levels in Srcwt-transfected cells.
Our data suggest that Ets1–DNA binding is activated by c-Src only
in 1833 cells, involving protein hypoacetylation, consistent with
Srcwt-dependent CXCR4 transactivation (Fig. 2B). In MDA-MB231
cells, however, HDACs blockade partly reduced Ets1 protein level
(Fig. 2C) and the Ets1 binding to CXCR4 promoter (Fig. 4B), still
permitting a certain CXCR4 expression, even if the functional role, i.e.
speciﬁc chemoinvasion towards CXCL12, possibly depended on
phosphorylation after TSA treatment (Figs. 2C and 1B).3.5. Transactivating activities of NF-κB and HIF-1 were differently
regulated by c-Src/HDACs depending on cell aggressiveness
The binding sites of NF-κB (p65) and HIF-1 are adjacent to those for
Ets1 on CXCR4 promoter (−2060/+19) (Fig. 5), leading to suppose a
possible cooperative function. Gene expression depends, in fact, on the
speciﬁcity of the stimulus and the interaction of transcription factors
showing consensus sites on the gene promoter. Transcription factors do
not work alone but in cooperation. The transcriptional properties of a
particular factor are inﬂuenced either by its position, relative to other
factors bound to a given promoter, or by the abundance of transcrip-
tional cofactors in a given cell type in a certain context [45]. This
regulatory mechanism might explain differences in Ets1 activity in
response to Srcwt in the two cell lines used.
As shown in Fig. 5A, the activity of the construct driven by the
multimer of NF-κB-consensus sequences was 2.5-fold higher in MDA-
Fig. 5. Transcription-factor transactivating activities in Srcwt-transfected cells, and role of HDACs. (A and B) The cells were transiently transfected with the indicated gene reporters,
expression vectors and siRNAs (HDAC1 plus 3). The histograms report the absolute values for Fireﬂy/Renilla luciferase activity ratios. Columns, mean of three independent
experiments done in triplicate; bars, S.E. *Pb0.05; **Pb0.005; ***Pb0.001 vs corresponding control value. ○○Pb0.005 vsMDA-MB231 control value. ΔΔPb0.005; ΔΔΔPb0.001 vs 1833-
Srcwt transfected cells. (C) Schematic representation of the different regulatorymechanisms and events controlling CXCR4 expression inMDA-MB231 and 1833 cells, exposed to TSA
or Srcwt. HIF-1 is inactive in MDA-MB231 cells [10,35]. TSA inhibits NF-κB activity and activates Ets1 [11].
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under basal conditions, in agreementwith our previousworks [10,35].
Both Srcwt transfection and HDACs blockade reduced NF-κB luciferase
activity in MDA-MB231 and 1833 cells. Differently, in 1833 cells Srcwt
transfection activated the luciferase activity of HRE-multimer con-
struct, while being prevented by concomitant HDACs blockade.
Thus, the possible functional interaction of the transcription
factors was examined (Fig. 5B), transfecting the gene reporter driven
by HRE multimer in the presence of ΔEts1. In 1833 cells, the HRE-
luciferase activity doubled after c-Src overexpression, and ΔEts1
largely prevented this stimulatory effect.
Fig. 5C shows a schematic representation of the data. In MDA-
MB231 cells, TSA is known to activate Ets1 and to inhibit NF-κB
activity [11]. CXCR4 might be a gene-target of TSA-stimulated Ets1,
even if post-translational regulation involving tyrosine phosphoryla-
tion was probably critical for the functional role in chemoinvasion.
Srcwt seemed to cause CXCR4 degradation. In 1833 cells, CXCR4 was
induced by Srcwt, possibly followed by nuclear translocation and
protein phosphorylation/stabilization without degradation.
4. Discussion
We give evidence that c-Src inﬂuenced spontaneous invasiveness
and CXCR4-mediated chemoinvasion of 1833-bone metastatic cells
frommammary carcinoma. c-Src seemed to be speciﬁcally involved in
nuclear CXCR4 phosphorylation and stability, impairing degradation
of the chemokine receptor at difference with parental MDA-MB231
cells. These molecular mechanisms might regulate the signaling
downstream, in addition to the known role played by multiple-serine
kinases in the CXCR4 function. Numerous serine-phosphorylation
sites have been suggested to control CXCL12- and PKC-mediated
CXCR4 signaling, internalization and degradation [15]. Phosphorylat-
ed CXCR4 is the active form of the receptor associated with the
metastatic risk [17]. The c-Src-dependent transactivation network,
leading to CXCR4 expression and phosphorylation, might inﬂuence
morphodynamic and molecular changes allowing the maintenance of
migratory dissemination, possibly also after abrogation of pericellular
proteolysis. In fact, metastasis shows migratory compensation
strategies that make difﬁcult to devise antimetastatic therapies [38].
The ability to distinguish phosphorylated CXCR4will be invaluable for
the analysis of the role of CXCR4 in cancer, and the development of
CXCR4 antagonist therapy [46]. CXCR4 is representative of trans-
membrane proteins expressed on the surface of normal and/or cancer
stem cells. Small molecule compounds or human antibody targeted to
CXCR4 have promising preclinical applications for cancer therapeu-
tics, focusing on cancer stem cells of the primary lesion as well as
metastasis or recurrence niches, such as bone marrow and peritoneal
cavity [47].
We suggest that c-Src overexpression was a critical molecular event
contributing to the remarkable plasticity of 1833-gene expression
proﬁle, in comparisonwithparentalMDA-MB231 cells.Our presentdata
demonstrated that only in 1833metastatic cells c-Src induced CXCR4. In
addition, in 1833 cells c-Src is a signal transducer of Met, another key
receptor for bonemetastatization of breast cancer and for the cross-talk
with bone microenvironment [9]. Therefore, through c-Src expression
1833 cells might become responsive to CXCL12 and HGF, bone
microenvironmental stimuli acting via CXCR4 and Met receptors. Both
CXCR4 (G protein-coupled receptor, GPCR) and Met (tyrosine kinase
receptor) might inﬂuence the metastatic phenotype, and both possibly
trigger critical signaling at nuclear level, even if the data at regard are
very scarce [9,10,48]. The role of other nuclearly-located GPCRs for
bioactive lipoids, such as PGE2 and PAF, has never been investigated in
bone metastases [49].
Metastatic cells show adaptability to biological and physical
microenvironmental stimuli that are likely to control gene transcription
at epigenetic level, but the molecular mechanisms are still largelyunknown andwould include c-Src/Ets1 signaling.When overexpressed,
c-Src enhanced Ets1–DNAbinding to CXCR4 gene promoter, the CXCR4-
transactivating activity, the cytosolic protein level and phosphorylation
of CXCR4 in 1833 cells. Noteworthy, multiple levels of regulation of
CXCR4 by c-Src occurred in 1833 cells, possibly including tyrosine
phosphorylation and the stabilization at nuclear level. Not only an
electrophoretic mobility shift of CXCR4 protein was observed in nuclei
of control 1833, when comparedwithMDA-MB231 cells, but also Srcwt
stressed the phenomenon giving an upper phosphorylation band
probably important for the CXCR4 functionality.
This is the ﬁrst time that nuclear CXCR4-tyrosine phosphorylation
in response to c-Src overexpression has been observed with a role in
receptor stabilization by impairing CXCR4 degradation, and in the
maintenance of CXCR4-dependent signal responsive to bone-metas-
tasis microenvironment. PKC-mediated phosphorylation in Ser-324/5
is known, instead, to drive receptor degradation [15]. This regulatory
mechanism might be similar to that of β-catenin, i.e. diverse amino
acid phosphorylation in serine or tyrosine might have opposite effects
enhancing or reducing ubiquitin-dependent degradation [9,50].
However, phosphorylation seems also responsible for regulating
CXCR4 trafﬁcking into non-lysosomal compartments including recy-
cling endosomes [51]. Tyrosine phosphorylation of CXCR4 might
inﬂuence other two regulatory mechanisms for GPCRs, i.e. the
deubiquitinating enzyme UPS8 and β-arrestin, that promote trafﬁck-
ing and degradation of CXCR4 receptor [41,42]. UPS8 loss of function
diminishes CXCR4 turnover, inducing receptor accumulation on
enlarged early endosomes—positive for hepatocyte growth factor-
regulated substrate—and affecting ERK signaling and intracellular
trafﬁcking [42]. β-arrestin controls the amount of ubiquitinated-
CXCR4 that is degraded in the endosomes [41].
CXCR4 is overexpressed in at least 23 types of cancer [52], with
dysregulation of CXCR4 transcription, signaling and trafﬁcking [15].
Altogether, multiple serines, threonines and tyrosines can be
phosphorylated in response to both ligand binding or activity in
parallel signaling pathways, making the deﬁnition of an activated,
phosphorylated form of the receptor complex [46].
Direct or indirect c-Src-dependent phosphorylation of CXCR4
might occur in early endosomes, followed by nuclear transfer, even if
we cannot exclude intranuclear tyrosine phosphorylation. Endosomes
are key signaling “stations” (signaling endosomes), endowed of
multiple functions, that generate unique signals prohibited at plasma
membrane, permitting signal diversiﬁcation and speciﬁcity [53]. Ideal
features of endosomes include two or more simultaneous interac-
tions, because of limited surface area of endosomes, and microtubule-
mediated transport of molecules from plasma membrane to the
nucleus. Altogether, these molecular mechanisms might contribute to
modulate the metastatic potential of breast carcinoma cells, by
inherent host-derived metastatic risk factor(s) activating CXCR4.
The exact signiﬁcance of CXCR4 in 1833-cell nuclei is not clear, and
a role in speciﬁc signaling for breast-carcinoma metastasis migration
can be suggested. CXCR4 nuclear localization is related to invasive and
metastatic trait of renal carcinoma, exerting transcriptional regulation
of genes that control invasion, migration and chemoattraction [54]. A
diffuse immunoﬂuorescence signal for CXCR4 throughout prostate
cancer cell, including nuclei, is consistently reported, and CXCR4-
mediated migration was through the ERK1/2 pathway [55]. Hassan et
al. observe by immunohistochemical analysis cytoplasmic and nuclear
expression of CXCR4 and the phosphorylated form, the latter being
related to breast carcinoma progression [17].
We show that hypoacetylationmediated gene-expression enhance-
ment of CXCR4 via c-Src/Ets1 activity, possibly by inﬂuencing c-Src
promoter [11,26] and Ets1-binding activities. In 1833 metastatic cells,
the knocking down of HDACs 1 and 3 prevented indeed Srcwt-
dependent Ets1 binding to the consensus sequence on CXCR4promoter.
Consistently, in response to siRNAs for HDACs, 1833-cell migration was
reduced [35]. Inmammarymetastatic cells HDACsmight be coactivators
1775P. Bendinelli et al. / Biochimica et Biophysica Acta 1813 (2011) 1767–1776of Ets1, as previously shown for HIF-1 and NF-κB [35]. Acetylation state
of histones H3 and H4 is associated with active chromatin and gene
expression, so we would expect the treatment with HDAC inhibitors to
induce a general increase in gene expression proﬁle. However, the
available data indicate that HDAC inhibitors cause transcriptional
changes of a limited set of genes, and that the number of upregulated
and downregulated genes is very similar [56]. β-arrestins are endocytic
adaptor proteins downstream of activated CXCR4, regulating the
signaling pathway that includes c-Src [15]. In addition, β-arrestins
function as nuclear messenger, regulating transcription in several ways
also interactingwith nucleic-acid bindingproteins [53]. Thus,we cannot
exclude that β-arrestins play a role also in metastasis nuclear-
transactivation pathway.
In conclusion, only in 1833-bone metastatic cells Ets1 was
transcriptionally functional and participated in CXCR4 induction
under c-Src-overexpression conditions involving HDACs. Based on our
results, Ets1 seemed to cooperate with other transcription factors on
CXCR4 promoter, and was phosphorylated possibly recruiting CREB-
binding protein/p300 coactivator [57]. Therefore, these regulatory
mechanism(s) dependedon the cell typeand aggressiveness. Consistent
with HIF-1 activation by phosphorylated c-Src, blocked by Ets1-
dominant negative, Ets1 might cooperate with HIF-1 to c-Src response.
We have shown that 1833 but not MDA-MB231 cells are responsive to
hypoxia, because of HIF-1 functionality due to stabilization of α and β
subunits [10]. This network of molecular events might explain the key
differences between poorly and highly metastatic cells, being possibly
related to metastatic mode of migration that reﬂects supramolecular
plasticity mechanisms. In contrast, in MDA-MB231 cells under basal
conditions NF-κB activitywas elevated possibly contributingwith Ets1–
DNA binding to CXCR4 expression. Srcwt enhanced nuclear CXCR4
degradation, while TSA overexpressed cytosolic CXCR4 in a phosphor-
ylated form, suggesting the latter as the molecular mechanism
positively affecting chemoinvasion.
Here, we extend and deepen the knowledge on the function of c-
Src in relation to the homing of metastatic cells via CXCR4, extensible
to angiogenesis and growth/survival of bone metastasis [58]. It has
been suggested that the behavior of cell homing to the bone may
include a direct vascular pathway, highly permeable vascular
sinusoids, chemotactic factors produced by marrow stromal cells
such as CXCL12, and synthesis of growth factors by resident cells
within the bone and the bone marrow, that support the survival and
proliferation of metastatic cells [59]. Studies are in progress to clarify
the role of c-Src expression in human specimens of bone metastasis of
breast cancer as predictive biomarker for the further advancement of
epigenetic targets, with signiﬁcant impact on deﬁning the clinical
utility of HDAC inhibitors and subset of responsivemetastasis-bearing
patients [60].
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